Targeting on the reg.
Regorafenib targets all kinds of tyrosine kinases and, when given for recurrent glioblastoma, improves overall survival over the standard lomustine in this phase 2 trial. | Lombardi, Lancet Oncol 2018
Search This Blog
With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
Comments
Post a Comment